Imagion Biosystems Limited is pleased to share news of research published by collaborators from the University of Sydney demonstrating that Imagion’s iron oxide nanoparticles enable low-field magnetic resonance imaging, which could provide a significant advancement in medical imaging by reducing the cost and improving the accessibility of MRI. This research reinforces the significance of the clinical and commercial opportunity for Imagion’s nanoparticles.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)
